Impact of restricting access to high-cost medications for hepatocellular carcinoma

References

• Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 127(12), 2893–2917 (2010).
   PubMed Web of Science ®Google Scholar
• Deuffic S, Poynard T, Buffat L, Valleron AJ. Trends in primary liver cancer. Lancet 351(9097), 214–215 (1998).
   PubMed Web of Science ®Google Scholar
• El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N. Engl. J. Med. 340(10), 745–750 (1999).
   PubMed Web of Science ®Google Scholar
• Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 362(9399), 1907–1917 (2003).
   PubMed Web of Science ®Google Scholar
• Lo CM, Ngan H, Tso WK et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35(5), 1164–1171 (2002).
   PubMed Web of Science ®Google Scholar
• Llovet JM, Real MI, Montaña X et al.; Barcelona Liver Cancer Group. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359(9319), 1734–1739 (2002).
   PubMed Web of Science ®Google Scholar
• Lopez PM, Villanueva A, Llovet JM. Systematic review: evidence-based management of hepatocellular carcinoma – an updated analysis of randomized controlled trials. Aliment. Pharmacol. Ther. 23(11), 1535–1547 (2006).
   PubMed Web of Science ®Google Scholar
• Wilhelm SM, Carter C, Tang L et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the Raf/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64(19), 7099–7109 (2004).
   PubMed Web of Science ®Google Scholar
• Liu L, Cao Y, Chen C et al. Sorafenib blocks the Raf/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res. 66(24), 11851–11858 (2006).
   PubMed Web of Science ®Google Scholar
• Strumberg D, Richly H, Hilger RA et al. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J. Clin. Oncol. 23(5), 965–972 (2005).
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Schwartz L, Ricci S et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J. Clin. Oncol. 24(26), 4293–4300 (2006).
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V et al. SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359(4), 378–390 (2008).
   PubMed Web of Science ®Google Scholar
• Cheng AL, Kang YK, Chen Z et al. Efficacy and safety of sorafenib in patients in the Asia–Pacific region with advanced hepatocellular carcinoma: a Phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 10(1), 25–34 (2009).
   PubMed Web of Science ®Google Scholar
• Zhu AX, Clark JW. Commentary: sorafenib use in patients with advanced hepatocellular carcinoma and underlying Child–Pugh B cirrhosis: evidence and controversy. Oncologist 14(1), 67–69 (2009).
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Amadori D, Santoro A et al. Is sorafenib (S) safe and effective in patients (pts) with hepatocellular carcinoma (HCC) and Child–Pugh B (CPB) cirrhosis? Presented at: The 2008 American Society of Clinical Oncology Annual Meeting. Chicago, IL, USA, 30 May–3 June 2008.
   Google Scholar
• Pinter M, Sieghart W, Graziadei I et al. Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis. Oncologist 14(1), 70–76 (2009).
   PubMed Web of Science ®Google Scholar
• Wörns MA, Weinmann A, Pfingst K et al. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis. J. Clin. Gastroenterol. 43(5), 489–495 (2009).
   PubMed Web of Science ®Google Scholar
• Schütte K, Zimmermann L, Bornschein J et al. Sorafenib therapy in patients with advanced hepatocellular carcinoma in advanced liver cirrhosis. Digestion 83(4), 275–282 (2011).
   PubMed Web of Science ®Google Scholar
• Lencioni R, Marrero J, Venook A, Ye SL, Kudo M. Design and rationale for the non-interventional Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma and of its Treatment with Sorafenib (GIDEON) study. Int. J. Clin. Pract. 64(8), 1034–1041 (2010).
   PubMed Web of Science ®Google Scholar
• Marrero JA, Lencioni R, Kudo M et al. Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma and of its Treatment with Sorafenib (GIDEON) second interim analysis in more than 1500 patients: clinical findings in patients with liver dysfunction. Presented at: The 2011 American Society of Clinical Oncology Annual Meeting. Chicago, IL, USA, 3–7 June 2011.
   Google Scholar
• NICE. Sorafenib for the Treatment of Advanced Hepatocellular Carcinoma. NICE, London, UK (2010).
   Google Scholar
• Zhang Z, Zhou X, Shen H, Wang D, Wang Y. Phosphorylated ERK is a potential predictor of sensitivity to sorafenib when treating hepatocellular carcinoma: evidence from an in vitro study. BMC Med. 7, 41 (2009).
   PubMed Web of Science ®Google Scholar
• Roberts PJ, Der CJ. Targeting the Raf–MEK–ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 26(22), 3291–3310 (2007).
   PubMed Web of Science ®Google Scholar
• Llovet JM, Pena C, Shan M, Lathia C, Bruix J. Biomarkers predicting outcome of patients with advanced hepatocellular carcinoma (HCC) randomized in the Phase III SHARP trial. Presented at: The American Association for the Study of Liver Diseases 59th Annual Meeting. San Francisco, CA, USA, 31 October–4 November 2008.
   Google Scholar
• Yau T, Yao TJ, Chan P et al. The significance of early 𝛂-fetoprotein level changes in predicting clinical and survival benefits in advanced hepatocellular carcinoma patients receiving sorafenib. Oncologist 16(9), 1270–1279 (2011).
   PubMed Web of Science ®Google Scholar
• Printz C. Clinical trials of note. Sorafenib as Adjuvant Treatment in the Prevention of Disease Recurrence in Patients with Hepatocellular Carcinoma (HCC) (STORM). Cancer 115, 4646 (2009).
   PubMedGoogle Scholar
• Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 37(2), 429–442 (2003).
   PubMed Web of Science ®Google Scholar
• Li X, Feng GS, Zheng CS, Zhuo CK, Liu X. Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level. World J. Gastroenterol. 10(19), 2878–2882 (2004).
   PubMed Web of Science ®Google Scholar
• Xiong ZP, Yang SR, Liang ZY et al. Association between vascular endothelial growth factor and metastasis after transcatheter arterial chemoembolization in patients with hepatocellular carcinoma. Hepatobiliary Pancreat. Dis. Int. 3(3), 386–390 (2004).
   PubMedGoogle Scholar
• Sergio A, Cristofori C, Cardin R et al. Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness. Am. J. Gastroenterol. 103(4), 914–921 (2008).
   PubMed Web of Science ®Google Scholar
• Kudo M, Imanaka K, Chida N et al. Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur. J. Cancer 47(14), 2117–2127 (2011).
   PubMed Web of Science ®Google Scholar
• Chung Y, Kim B, Chen J et al. Study in Asia of the combination of transarterial chemoembolization (TACE) with sorafenib in patients with hepatocellular carcinoma (HCC) trial (START): second interim analysis and efficcy analysis. Presented at: The 2010 American Society of Clinical Oncology Annual Meeting. Chicago, IL, USA, 4–8 June 2010.
   Google Scholar
• Maddala YK, Stadheim L, Andrews JC et al. Drop-out rates of patients with hepatocellular cancer listed for liver transplantation: outcome with chemoembolization. Liver Transpl. 10(3), 449–455 (2004).
   PubMed Web of Science ®Google Scholar
• Hoffman K, Glimm H, Radeleff B et al. Prospective, randomized, double-blind multi-center, phase III clinical study on transarterial chemoembolization with sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation – HeiLivCa (ISRCTN24081794). BMC Cancer 8, 349 (2008).
   PubMed Web of Science ®Google Scholar
• Vincent P, Zhang X, Chen C et al. Preclinical chemotherapy with the Raf kinase inhibitor BAY 43-9006 in combination with gefitinib, vinorelbine, gemcitabine or doxorubicin. Presented at: the 94th Annual Meeting of the American Association for Cancer Research. Washington, DC, USA, 11–14 July 2003.
   Google Scholar
• Richly H, Henning BF, Kupsch P et al. Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors. Ann. Oncol. 17(5), 866–873 (2006).
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Johnson P, Knox JJ et al. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. JAMA 304(19), 2154–2160 (2010).
   PubMed Web of Science ®Google Scholar
• Cheng A, Kang Y, Lin D et al. Phase III trial of sunitinib (Su) versus sorafenib (So) in advanced hepatocellular carcinoma (HCC). J. Clin. Oncol. 29(Suppl.) (2011) (Abstract 4000).
   Google Scholar
• Palmer DH, Hussain SA, Smith AJ, Hull D, Johnson PJ. Sorafenib for advanced hepatocellular carcinoma (HCC): impact of rationing in the United Kingdom. J. Clin. Oncol. 28(Suppl.) (2010) (Abstract e14516).
   Google Scholar
• Bolondi L, Tak WY, Gasbarrini A et al. Phase II safety study of the oral multikinase inhibitor Regorafenib (BAY 73-4506) as second-line therapy in patients with hepatocellular carcinoma. Eur. J. Cancer 47, S464 (2011).
   Google Scholar
• Alberts SR, Fitch TR, Kim GP et al. Cediranib (AZD2171) in patients with advanced hepatocellular carcinoma: a Phase II North Central Cancer Treatment Group Clinical Trial. Am. J. Clin. Oncol. 35(4), 329–333 (2012).
   PubMed Web of Science ®Google Scholar
• Hsu C, Yang TS, Huo TI et al. Vandetanib in patients with inoperable hepatocellular carcinoma: a Phase II, randomized, double-blind, placebo-controlled study. J. Hepatol. 56(5), 1097–1103 (2012).
   PubMed Web of Science ®Google Scholar
• Kanai F, Yoshida H, Tateishi R et al. A Phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinoma. Cancer Chemother. Pharmacol. 67(2), 315–324 (2011).
   PubMed Web of Science ®Google Scholar
• Yau T, Chen PJ, Chan P et al. Phase I dose-finding study of pazopanib in hepatocellular carcinoma: evaluation of early efficacy, pharmacokinetics, and pharmacodynamics. Clin. Cancer Res. 17(21), 6914–6923 (2011).
   PubMed Web of Science ®Google Scholar